07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: p53

Cancer INDICATION: Lymphoma Mouse studies suggest inhibiting p53 could help prevent radiotherapy-induced thymic lymphoma and acute hematologic toxicity. In normal mice receiving whole-body irradiation, p53 knockdown decreased acute apoptosis of thymic and bone marrow cells,...
07:00 , Sep 30, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tumor protein p53 (TP53; p53) Cell culture studies identified short oligonucleotide inhibitors of p53 synthesis that could help prevent chemotherapy-induced damage to healthy cells....
07:00 , Sep 7, 2009 |  BioCentury  |  Regulation

On deck in AML

On deck in AML...
07:00 , Aug 27, 2009 |  BC Innovations  |  Targets & Mechanisms

Melanoma: eaten up inside

Autophagy's dual pro- and antiapoptotic roles make it hard to determine whether inducing the process could be a viable strategy to treat cancer. In melanoma, a team led by Spanish researchers thinks the answer is...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

Aezea cenersen sodium regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Aezea cenersen to treat chronic lymphocytic leukemia (CLL). The antisense oligonucleotide against p53 is in Phase II testing...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

AVI BioPharma, Eleos deal

The companies signed a cross-license agreement to develop antisense compounds targeting p53. Eleos gets an exclusive license to AVII's Neugene antisense chemistry to develop compounds targeting p53 to treat cancer, and AVII gets an exclusive...
07:00 , May 10, 2004 |  BioCentury  |  Finance

Midwest work ethic

Midwest work ethic...